On the other hand, in the last years, several studies have established positive associations between enhanced circulating visfatin/NAMPT levels and atherogenic inflammatory diseases, therefore supporting a role for visfatin as a potential biomarker of cardiovascular complications associated to metabolic disorders [45–47]. This evidence concerns the gene NAMPT and metabolic disease.